Sage Therapeutics, Inc. (NASDAQ:SAGE) Shares Acquired by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC lifted its stake in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) by 3,361.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 19,040 shares of the biopharmaceutical company’s stock after purchasing an additional 18,490 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Sage Therapeutics were worth $413,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in SAGE. Advisor Group Holdings Inc. raised its position in shares of Sage Therapeutics by 63.6% during the 1st quarter. Advisor Group Holdings Inc. now owns 11,406 shares of the biopharmaceutical company’s stock worth $378,000 after purchasing an additional 4,432 shares during the period. Bank of New York Mellon Corp raised its position in shares of Sage Therapeutics by 3.0% during the 1st quarter. Bank of New York Mellon Corp now owns 352,623 shares of the biopharmaceutical company’s stock worth $11,672,000 after purchasing an additional 10,134 shares during the period. MetLife Investment Management LLC acquired a new stake in shares of Sage Therapeutics during the 1st quarter worth approximately $34,000. Vanguard Group Inc. raised its position in shares of Sage Therapeutics by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 4,625,003 shares of the biopharmaceutical company’s stock worth $153,088,000 after purchasing an additional 46,762 shares during the period. Finally, First Trust Advisors LP raised its position in shares of Sage Therapeutics by 4.1% during the 1st quarter. First Trust Advisors LP now owns 844,652 shares of the biopharmaceutical company’s stock worth $27,958,000 after purchasing an additional 33,218 shares during the period. 99.22% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts recently issued reports on SAGE shares. Wedbush reissued a “neutral” rating and issued a $24.00 price objective on shares of Sage Therapeutics in a report on Wednesday. Bank of America lowered Sage Therapeutics from a “neutral” rating to an “underperform” rating and decreased their price objective for the stock from $24.00 to $14.00 in a report on Wednesday. Morgan Stanley increased their price objective on Sage Therapeutics from $20.00 to $22.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 28th. HC Wainwright reissued a “neutral” rating and issued a $28.00 price objective on shares of Sage Therapeutics in a report on Wednesday. Finally, Royal Bank of Canada increased their price objective on Sage Therapeutics from $21.00 to $26.00 and gave the stock a “sector perform” rating in a report on Thursday, February 15th. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, Sage Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $40.56.

Sage Therapeutics Stock Down 19.6 %

SAGE opened at $12.57 on Thursday. The firm has a market cap of $755.58 million, a PE ratio of -1.39 and a beta of 0.86. The business has a fifty day simple moving average of $20.06 and a 200-day simple moving average of $20.96. Sage Therapeutics, Inc. has a fifty-two week low of $10.92 and a fifty-two week high of $59.99.

Sage Therapeutics (NASDAQ:SAGE) last released its earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($0.55) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.28) by $0.73. The company had revenue of $77.97 million during the quarter, compared to analyst estimates of $60.15 million. Sage Therapeutics had a negative return on equity of 54.41% and a negative net margin of 626.32%. The company’s revenue for the quarter was up 2621.5% on a year-over-year basis. During the same quarter in the prior year, the company earned ($2.47) earnings per share. On average, equities research analysts anticipate that Sage Therapeutics, Inc. will post -6.06 EPS for the current fiscal year.

Sage Therapeutics Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.